Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-coat protein carrying self or non-self CD8 T cell epitopes against murine melanoma

Cancer Immunology, Immunotherapy

Volumn 54, Issue 6, 2005, Pages 611-622

  Brinkman, Marc ^a   Walter, Juergen ^a   Grein, Swen ^a   Thies, Michael J W ^a   Schulz, Torsten W ^a   Herrmann, Martin ^a,b   Reiser, Christian O A ^a   Hess, Juergen ^a  

^a Responsif GmbH   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

CD8 T cell response; Melanoma therapy; Pentamers; T cell epitope; TRP2 tumour antigen; Virus like particles

Indexed keywords

ANTIGEN; CD8 ANTIGEN; EPITOPE; OVALBUMIN[257-264]; PROTEIN VP1; PROTEIN VP1 OVALBUMIN[252-270]; PROTEIN VP1 TYROSINASE RELATED PROTEIN 2[180-192]; QUIL A; RECOMBINANT INTERLEUKIN 2; TETRAMER; TYROSINASE RELATED PROTEIN 2; TYROSINASE RELATED PROTEIN[180-188]; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER PREVENTION; CANCER REGRESSION; CANCER SURVIVAL; CANCER TRANSPLANTATION; CELL POPULATION; CELL SPECIFICITY; CELLULAR IMMUNITY; CHIMERA; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE COUNT; MELANOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYOMA VIRUS; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR IMMUNITY; VACCINATION; VIRUS PARTICLE;

ANIMALS; CAPSID PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; IMMUNIZATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; OVALBUMIN; PEPTIDE FRAGMENTS; POLYOMAVIRUS;

EID: 18044397111     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0655-0     Document Type: Conference Paper

References (37)

1. Abbing A, Blaschke UK, Grein S, Kretschmar M, Stark CMB, Thies MJW, Walter J, Weigand M, Woith DC, Hess J, Reiser COA (2004) Efficient intracellular delivery of a protein and a low molecular weight substance via recombinant polyomavirus-like particles. J Biol Chem 279:27410-27421
2. Bellone M, Cantarella D, Castiglioni P, Crosti MC, Ronchetti A, Moro M, Garancini MP, Casorati G, Dellabona P (2000) Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J Immunol 165:2651-2656
3. Beyer T, Herrmann M, Reiser C, Bertling W, Hess J (2001) Bacterial carriers and virus-like-particles as antigen delivery devices: role of dendritic cells in antigen presentation. Curr Drug Targets Infect Disord 1:287-302
4. Bloom MB, Perry-Lalley D, Robbins PF, Li Y, El-Gamil M, Rosenberg SA, Yang JC (1997) Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 185:453-459
5. Boisgerault F, Moron G, Leclerc C (2002) Virus-like particles: a new family of delivery systems. Exp Rev Vaccines 1:101-109
6. Brinkman M, Walter J, Jennes I, Neugebauer M, Bertling W, Grein S, Thies MJW, Weigand M, Beyer T, Herrmann M, Reiser COA, Hess J (2004) Recombinant murine polyoma virus-like-particles induce protective anti-tumour immunity. Lett Drug Des Disc 1:137-147
7. Bungener L, Idema J, ter Veer W, Huckriede A, Daemen T, Wilschut J (2002) Virosomes in vaccine development: induction of cytotoxic T lymphocyte activity with virosome-encapsulated protein antigens. J Liposome Res 12:155-163
8. Byers AM, Kemball CC, Moser JM, Lukacher AE (2003) Cutting edge: rapid in vivo CTL activity by polyoma virus-specific effector and memory CD8+ T cells. J Immunol 171:17-21
9. Celluzzi CM, Falo LD Jr (1997) Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity. J Invest Dermatol 108:716-720
10. Chackerian B, Lenz P, Lowy DR, Schiller JT (2002) Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 169(11):6120-6126
11. Da Silva DM, Pastrana DV, Schiller JT, Kast WM (2001) Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimerical human papillomavirus virus-like particle vaccines. Virology 290:350-360
12. Da Silva DM, Schiller JT, Kast WM (2003) Heterologous boosting increases immunogenicity of chimerical papillomavirus virus-like-particle vaccines. Vaccine 21:3219-3227
13. Deml L, Wild J, Wagner R (2004) Virus-like particles: a novel tool for the induction and monitoring for both T-helper and cytotoxic T-lymphocyte activity. Methods Mol Med 94:133-157
14. Doerries K (1996) Virus-host interactions and diagnosis of human polyomavirus-associated disease. Interviroloy 39:165-175
15. Freyschmidt EJ, Alsonso A, Hartmann G, Gissmann L (2004) Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol. Antivir Ther 9(4):479-489
16. Greenstone HL, Nieland JD, de Visser KE, de Brujin MLH, Kirnbauer R, Roden RBS, Lowy DR, Kast M, Schiller JT (1998) Chimerical papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 95:1800-1805
17. Hess J, Schaible U, Raupach B, Kaufmann SHE (2000) Exploiting the immune system: new vaccines against intracellular bacteria. Adv Immunol 75:1-88
18. Jung S, Unutmaz D, Wong P, Sano G, De los Santos K, Sparwasser T, Wu S, Vuthoori S, Ko K, Zavala F, Pamer EG, Littman DR, Lang RA (2002) In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 17:211-220
19. Lenz P, Day PM, Pang Y-YS, Frye SA, Jensen PN, Lowy DR, Schiller JT (2001) Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol 166:5346-5355
20. Lenz P, Thompson CD, Day PM, Bacot SM, Lowy DR, Schiller JT (2003) Interactioon of papillomavirus virus-like particles with human myeloid antigen-presenting cells. Clin Immunol 106(3):231-237
21. Li M, Davey GM, Sutherland RM, Kurts C, Lew AM, Hirst C, Carbone FR, Heath WR (2001) Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol 166:6099-6103
22. Moron G, Rueda P, Casal I, Leclerc C (2002) CD8alpha- CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8alpha and CD205 molecules. J Exp Med 195(10):1233-1245
23. Moron VG, Rueda P, Sedlik C, Leclerc C (2003) In vivo, dendritic cells can cross-present virus-like-particles using an endosome-to-cytosol pathway. J Immunol 171(5):2242-2240
24. Öhlschlaeger P, Osen W, Dell K, Faath S, Garcea RL, Jochmus I, Muller M, Pawlita M, Schafer K, Sehr P, Staib C, Sutter G, Gissmann L (2003) Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol 77:4635-4645
25. Parkhurst MR, Fitzgerald EB, Southwood S, Sette A, Rosenberg SA, Kawakami Y (1998) Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res 58:4895-4901
26. - dendritic cells: a dispensable role for TAP. Eur J Immunol 32:818-825
27. Scalzo AA, Elliott SL, Cox J, Gardner J, Moss DJ, Suhrbier A (1995) Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720). J Virol 69(2):1306-1309
28. Schreurs MWJ, Eggert AAO, de Boer AJ, Vissers JLM, van Hall T, Offringa R, Figdor CG, Adema GJ (2000) Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res 60:6995-7001
29. Sedlik C, Saron M, Sarraseca J, Casal I, Leclerc C (1997) Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc Natl Acad Sci USA 94:7503-7508
30. Shibagaki N, Udey MC (2003) Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma. Eur J Immunol 33:850-860
31. Stuhler G, Walden P (eds) (2002) T cells in tumor immunity in Cancer Immune Therapy. Wiley, Weinheim
32. Van Elsas A, Sutmuller RPM, Hurwitz AA, Ziskin J, Villasenor J, Medema J-P, Overwijk WW, Restifo NP, Melief CJM, Offringa R, Allison JP (2001) Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on ctotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 194:481-489
33. Wang RF, Wang HY (2002) Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat Biotechnol 20:149-154
34. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA (1996) Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 184:2207-2216
35. Wang HY, Fu T, Wang G, Zeng G, Perry-Lalley DM, Yang JC, Restifo NP, Hwu P, Wang R-F (2002) Induction of CD4 T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J Clin Invest 109:1463-1470
36. Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Teates D, Neese P, Grosh WW, Petroni G, Engelhard VH, Slingluff CL Jr (2001) Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. Int J Cancer 92:703-711
37. Zhou Y, Bosch ML, Salgaller ML (2002) Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J Immunother 25:289-303